Search

Author/Creator Reisman, Arlene

2. Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer. (June 2020)

Authors:
Peters, Solange; Shaw, Alice T.; Besse, Benjamin; Felip, Enriqueta; Solomon, Benjamin J.; Soo, Ross A.; Bearz, Alessandra; Gadgeel, Shirish M.; Lin, Chia-Chi; Kao, Steven; Seto, Takashi; Masters, Elizabeth T.; Abbattista, Antonello; Clancy, Jill S.; Thurm, Holger; Reisman, Arlene; Peltz, Gerson; ...
Journal:
Lung cancer
Issue:
Volume 144(2020)
Page Start:
10
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer. (December 2022)

Authors:
Mazieres, Julien; Iadeluca, Laura; Shaw, Alice T.; Solomon, Benjamin J.; Bauer, Todd M.; de Marinis, Filippo; Felip, Enriqueta; Goto, Yasushi; Kim, Dong-Wan; Mok, Tony; Reisman, Arlene; Thurm, Holger; Polli, Anna M.; Liu, Geoffrey
Journal:
Lung cancer
Issue:
Volume 174(2022)
Page Start:
146
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗